This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Axelia Oncology Pty Ltd. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025-2026
Title: David Jackson - Innovator in Respiratory Infection Treatment
Introduction
David Jackson is a notable inventor based in Melbourne, Australia. He has made significant contributions to the field of medical research, particularly in the development of compounds aimed at treating respiratory infections.
Latest Patents
David holds a patent for "Optimised Compounds." This invention relates to TLR2 agonist compounds and their compositions. The use of these compounds and compositions is focused on the prevention and/or treatment of respiratory infections, as well as diseases or conditions associated with viral or bacterial infections. He has 1 patent to his name.
Career Highlights
David is currently associated with Axelia Oncology Pty Ltd, where he continues to work on innovative solutions in the medical field. His expertise and dedication have positioned him as a valuable asset in the research community.
Collaborations
David collaborates with talented individuals such as Ian Holmes and Weiguang Zeng. Their combined efforts contribute to advancing research and development in their respective areas.
Conclusion
David Jackson's work in developing TLR2 agonist compounds showcases his commitment to improving healthcare outcomes. His innovative approach to treating respiratory infections highlights the importance of research in combating health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile